Aktis Oncology Inc.
AKTS | NASDAQ
$14.62
-$1.31 (-8.22%)
Nov 2, 2026, 10:42 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|---|---|
Revenue | 3.38M | 3.23M | 1.87M | 1.58M | 1.6M | 1.45M | 933K |
Cost of Revenue | 879K | 652K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 2.51M | 2.58M | 1.87M | 1.58M | 1.6M | 1.45M | 933K |
Operating Income | -28.9M | -22.71M | -17.38M | -18.2M | -20.96M | -18.14M | -15.64M |
Interest Income | 4.77M | 4.38M | 2.25M | 2.68M | 2.91M | 3.17M | 3.58M |
Pretax Income | -24.14M | -18.33M | -15.14M | -15.53M | -18.08M | -14.99M | -12.06M |
Net Income | -24.14M | -18.33M | -15.14M | -15.53M | -18.08M | -14.99M | -12.06M |
Selling & General & Admin | 6.12M | 5.25M | 2.51M | 3.06M | 3.68M | 3.35M | 3.94M |
Research & Development | 25.28M | 20.04M | 16.49M | 16.47M | 18.63M | 15.86M | 12.61M |
Other Expenses | n/a | n/a | 242K | 254K | 255K | 381K | 21K |
Operating Expenses | 31.4M | 25.28M | 19.25M | 19.78M | 22.56M | 19.59M | 16.57M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 32.28M | 25.93M | 19.25M | 19.78M | 22.56M | 19.59M | 16.57M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 55.32M | 55.28M | 53.4M | n/a | 52.52M | 34.86M | 52.52M |
Shares Outstanding (Diluted) | 55.32M | 55.28M | 53.4M | n/a | 52.52M | 34.86M | 52.52M |
EPS (Basic) | -0.44 | -0.33 | -0.28 | n/a | -0.34 | -0.43 | -0.23 |
EPS (Diluted) | -0.44 | -0.33 | -0.28 | n/a | -0.34 | -0.43 | -0.23 |
EBITDA | -28.02M | -17.67M | -14.44M | -17.61M | -20.41M | -17.66M | -11.62M |
EBIT | -28.9M | -18.33M | -15.14M | -18.2M | -20.96M | -18.14M | -12.06M |
Depreciation & Amortization | 879K | 652K | 695K | 598K | 552K | 484K | 441K |
Add to Watchlist
Select watchlists to add or remove AKTS